nach oben

Erschienen in:

01.01.2013 | Original paper

CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment

verfasst von: Elizabeth L. Barry, Elizabeth M. Poole, John A. Baron, Karen W. Makar, Leila A. Mott, Robert S. Sandler, Dennis J. Ahnen, Robert S. Bresalier, Gail E. McKeown-Eyssen, Cornelia M. Ulrich

Erschienen in: Cancer Causes & Control | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The cytochrome P450 2C9 enzyme (CYP2C9) is involved in metabolism of endogenous compounds, drugs, and procarcinogens. Two common nonsynonymous polymorphisms in CYP2C9 are associated with reduced enzyme activity: CYP2C9*2 (rs1799853, R144C) and CYP2C9*3 (rs1057910, I359L).

Methods

We investigated whether CYP2C9 genotype was associated with risk of colorectal adenoma and/or modified associations with aspirin treatment or cigarette smoking in a cohort of 928 participants in a randomized trial of aspirin chemoprevention. Generalized linear regression was used to compute relative risks (RRs) and 95 % confidence intervals (95 % CIs). Multiplicative interactions terms were used to assess effect modification.

Results

CYP2C9 genotype was associated with increased risks for adenoma recurrence of 29 % (RR = 1.29, 95 % CI 1.09–1.51) for ≥1 variant allele (CYP2C9*2 or *3) and 47 % (RR = 1.47, 95 % CI 1.19–1.83) for ≥1 CYP2C9*3 allele. The risk for advanced lesions or multiple (≥3) adenomas was increased by 64 % (RR = 1.64, 95 % CI 1.18–2.28) for ≥1 variant allele (CYP2C9*2 or *3) and 79 % (RR = 1.79, 95 % CI 1.16–2.75) for ≥1 CYP2C9*3 allele. Genotype modified associations with smoking, but not aspirin treatment. The adenoma risk was increased by 26 % (RR = 1.26, 95 % CI 0.99–1.58) for former smokers and 60 % (RR = 1.60, 95 % CI 1.19–2.15) for current smokers among wild-type individuals, but there was no increased risk among individuals with ≥1 variant allele (CYP2C9*2 or *3) (p _interaction = 0.04).

Conclusions

Carriers of CYP2C9 variants with lower enzyme activity have increased overall risk of colorectal adenoma but reduced adenoma risk associated with cigarette smoking. These results may be due to effects on the synthesis of endogenous eicosanoids and/or reduced activation of procarcinogens in smoke by CYP2C9 variants.

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef

Nebert DW, Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155–1162PubMedCrossRef

Panigrahy D, Kaipainen A, Greene ER, Huang S (2010) Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev 29:723–735PubMedCrossRef

Shou M, Krausz KW, Gonzalez FJ, Gelboin HV (1996) Metabolic activation of the potent carcinogen dibenzo[a, h]anthracene by cDNA-expressed human cytochromes P450. Arch Biochem Biophys 328:201–207PubMedCrossRef

Yun CH, Shimada T, Guengerich FP (1992) Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. Cancer Res 52:1868–1874PubMed

Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF (2009) New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab 10:1075–1126PubMedCrossRef

Shou M, Korzekwa KR, Crespi CL, Gonzalez FJ, Gelboin HV (1994) The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Mol Carcinog 10:159–168PubMedCrossRef

Zhou SF, Zhou ZW, Huang M (2010) Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278:165–188PubMedCrossRef

Rokitta D, Fuhr U (2010) Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants. Curr Drug Metab 11:153–161PubMedCrossRef

10.

Wang B, Wang J, Huang SQ, Su HH, Zhou SF (2009) Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab 10:781–834PubMedCrossRef

11.

Van Booven D, Marsh S, McLeod H et al (2010) Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 20:277–281PubMed

12.

Lindh JD, Holm L, Andersson ML, Rane A (2009) Influence of CYP2C9 genotype on warfarin dose requirements–a systematic review and meta-analysis. Eur J Clin Pharmacol 65:365–375PubMedCrossRef

13.

Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD (2001) CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 61:3566–3569PubMed

14.

Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS (2004) A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol 2:704–712PubMedCrossRef

15.

Hubner RA, Muir KR, Liu JF et al (2006) Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence. Clin Cancer Res 12:6585–6589PubMedCrossRef

16.

Samowitz WS, Wolff RK, Curtin K et al (2006) Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin Gastroenterol Hepatol 4:894–901PubMedCrossRef

17.

Chan AT, Zauber AG, Hsu M et al (2009) Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 136(2127–36):e1CrossRef

18.

Cleary SP, Cotterchio M, Shi E, Gallinger S, Harper P (2010) Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Am J Epidemiol 172:1000–1014PubMedCrossRef

19.

Northwood EL, Elliott F, Forman D et al (2010) Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics 20:315–326PubMedCrossRef

20.

Baron JA, Cole BF, Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899PubMedCrossRef

21.

Cole BF, Baron JA, Sandler RS et al (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297:2351–2359PubMedCrossRef

22.

Enayetallah AE, French RA, Thibodeau MS, Grant DF (2004) Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 52:447–454PubMedCrossRef

23.

Enayetallah AE, French RA, Grant DF (2006) Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. J Mol Histol 37:133–141PubMedCrossRef

24.

Martinez ME, Baron JA, Lieberman DA et al (2009) A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology 136:832–841PubMedCrossRef

25.

Yasar U, Lundgren S, Eliasson E et al (2002) Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 299:25–28PubMedCrossRef

26.

Yasar U, Bennet AM, Eliasson E et al (2003) Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13:715–720PubMedCrossRef

27.

Cross JT, Poole EM, Ulrich CM (2008) A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J 8:237–247PubMedCrossRef

28.

Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6:130–140PubMedCrossRef

29.

The Tobacco and Genetics Consortium (2010) Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 42:441–447CrossRef

30.

Loukola A, Broms U, Maunu H et al (2008) Linkage of nicotine dependence and smoking behavior on 10q, 7q and 11p in twins with homogeneous genetic background. Pharmacogenomics J 8:209–219PubMedCrossRef

31.

Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF (2011) Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 103:1342–1346PubMedCrossRef

32.

Shimada T (2006) Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 21:257–276PubMedCrossRef

33.

Ding YS, Ashley DL, Watson CH (2007) Determination of 10 carcinogenic polycyclic aromatic hydrocarbons in mainstream cigarette smoke. J Agric Food Chem 55:5966–5973PubMedCrossRef

34.

Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB (2008) Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology 134:388–395PubMedCrossRef

35.

Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P (2008) Smoking and colorectal cancer: a meta-analysis. JAMA 300:2765–2778PubMedCrossRef

36.

Tsoi KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJ (2009) Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 7(682–8):e1–e5PubMed

37.

Limsui D, Vierkant RA, Tillmans LS et al (2010) Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 102:1012–1022PubMedCrossRef

38.

Boland CR, Goel A (2010) Clearing the air on smoking and colorectal cancer. J Natl Cancer Inst 102:996–997PubMedCrossRef

39.

Campbell PT, Curtin K, Ulrich CM et al (2009) Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut 58:661–667PubMedCrossRef

Titel: CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment
verfasst von: Elizabeth L. Barry
Elizabeth M. Poole
John A. Baron
Karen W. Makar
Leila A. Mott
Robert S. Sandler
Dennis J. Ahnen
Robert S. Bresalier
Gail E. McKeown-Eyssen
Cornelia M. Ulrich
Publikationsdatum: 01.01.2013
Verlag: Springer Netherlands
Erschienen in: Cancer Causes & Control / Ausgabe 1/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-012-0088-6

Springer Medizin

CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment